GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » Loans Receivable

Fortrea Holdings (FRA:K67) Loans Receivable : €0 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Loans Receivable?

Fortrea Holdings's Loans Receivable for the quarter that ended in Jun. 2024 was €0 Mil.


Fortrea Holdings Loans Receivable Historical Data

The historical data trend for Fortrea Holdings's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Loans Receivable Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Loans Receivable
- - - -

Fortrea Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fortrea Holdings Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Fortrea Holdings Loans Receivable Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortrea Holdings Business Description

Traded in Other Exchanges
Address
8 Moore Drive, Durham, NC, USA, 27709
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings Headlines

No Headlines